StockData

LivaNova vs TransMedics

LIVN and TMDX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LIVN and TMDX compare

LivaNova is the larger company, worth 1.6 times as much as TransMedics ($5.1B against $3.3B).

On earnings, TransMedics is cheaper: it trades at 24.4× trailing earnings, against 27.1× for LivaNova.

TransMedics grew revenue faster over the last twelve months (25.8% versus 12.4% for LivaNova).

TransMedics keeps more of each dollar of sales as profit, with a net margin of 22.7% compared with 12.8% at LivaNova.

TransMedics scores higher on the StockData Score (14 against 13 for LivaNova), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLIVNTMDX
Size and price
Market cap$5.1B$3.3B
Share price$91.92$93.91
Change, 1 year66.0%−18.3%
Change, 5 years10.3%329%
Beta (5Y)0.830.77
Employees3,300898
StockData Score
Total score1314 (better)
Valuation score05 (better)
Growth score4 (better)2
Performance score4 (better)3
Health score5 (better)4
Dividend score00
Valuation
P/E27.1×24.4× (better)
P/S3.4× (better)4.9×
P/B3.8× (better)6.3×
EV/EBITDA25.8×23.8× (better)
P/FCF34.1× (better)41.2×
FCF yield2.9% (better)2.4%
Fair value$69.65$131.38
Margin of safety−32.0%28.5% (better)
Growth
Revenue growth (TTM)12.4%25.8% (better)
Revenue growth, 5Y average8.2%88.2% (better)
Net income growth (TTM)–112%
EPS growth (TTM)–99.5%
Profitability
Gross margin68.1% (better)58.7%
Operating margin12.7% (better)12.2%
Net margin12.8%22.7% (better)
FCF margin10.1%11.8% (better)
Return on equity15.4%36.3% (better)
Return on invested capital18.2%–
Financial health
Debt / equity0.220.04 (better)
Net debt / EBITDA−1.19−3.84
Interest coverage5.0× (better)3.8×
Current ratio1.456.62 (better)
Altman Z-score2.712.91 (better)
Piotroski F-score56 (better)
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions108%100%
Held by insiders0.48%3.9%
Insider net buying, 12 months−$1.3M (better)−$4.2M
Short interest, % of float11.6%26.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.